RTM receives marketing authorisation for Fludeoxyglucose (18F)

We are happy to announce that RTM has received marketing authorization for ¹⁸F-FDG of 17 July 2018.

Fludeoxyglucose (¹⁸F) RTM 200 MBq/ml, solution for injection will become commercially available in The Netherlands in October, with roll-out to Belgium and Germany planned in 2019.

Other news

Production of novel diagnostic radionuclides in small medical cyclotrons

Employees from RTM and Radboudumc have published a new article: 'Production of novel diagnostic radi...

GMP-certificate received

Today we received our GMP-certificate!The results of the inspection were excellent and no shortcomin...

Cooperation RTM-Alliance Medical

It is with great pleasure that we announce our cooperation with Alliance Medical Group (AMG) regardi...

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...

News